Signup to have metrics tracked for this article

By signing up, social media discussions about Long-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two Years. will be collected and displayed on PubHawk. We'll also notify you by email on a monthly basis of any new updates captured on platforms like YouTube, Twitter/X, Bluesky, Facebook, LinkedIn, and more.
Your identifiable personal information will never be sold or shared to directly target you.

Please enter a valid email.
You must agree before submitting.

Example of Metrics tracking for this article:

Layout example
Long-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two Years.
Layout example